24.8 C
New York
Saturday, June 6, 2026

Tag: data insights

SCADA Market worth $20.05 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 30, 2025 /PRNewswire/ -- The global SCADA market is expected to grow from USD 12.89 billion in 2025 to USD 20.05...

OpenText and TELUS partner to deliver Canadian sovereign AI-powered solutions for government and business

WATERLOO, ON, July 30, 2025 /PRNewswire/ -- OpenText™ (NASDAQ: OTEX), (TSX: OTEX), the leading information management company, and TELUS, a world-leading communications technology company, today...

Onix Brings the Power of AI Agents and Agentspace to Customer Service with Acquisition of UJET Services Unit

Strengthening Onix's position as a leading partner for Google Cloud's Customer Engagement AI Suite (CES), Agentspace, and Agentic AI with preferred UJET CCaaS implementation...

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

Autonomous Agents Set to Revolutionise Transportation Management

Global research from Manhattan Associates finds integration difficulties and data quality remain significant hurdles for organisations looking to leverage AI across transportation management SYDNEY,...

DYE & DURHAM ISSUES STATEMENT IN RESPONSE TO ALLEGATIONS MADE BY FORMER CEO MATT PROUD

TORONTO, July 14, 2025 /CNW/ - Dye & Durham Limited ("Dye & Durham" or the "Company") (TSX: DND), a leading provider of cloud-based legal...

Dye & Durham Highlights New Leadership’s Commitment to Advancing Turnaround Initiatives and Maximizing Value for Shareholders

New leadership shares strategy to enable the Company to evaluate value-maximizingoptions from a position of strength Shareholders Need Not Take Any Action in Responseto Ex-CEO...

Questex’s Sensors Converge and Fierce Electronics Announce 2025 Best of Sensors Awards Winners

Honors Innovation, Leadership, and Excellence Driving the Future of Sensors, Electronics, and AI
Honors Innovation, Leadership, and Excellence Driving the Future of Sensors, Electronics, and AI

GoNetZero™ and AlliedOffsets Partner to Help Businesses Navigate the Voluntary Carbon Market with Confidence

SINGAPORE and LONDON, June 25, 2025 /PRNewswire/ -- GoNetZero™, a global decarbonisation enabler in clean energy procurement and carbon management, announces a new strategic alliance...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsData insights